Unleashing the T-cell army: cancer immunotherapy at Roche

Cancer immunotherapy helps us enhance our immune systems so that they’re able to fight cancer, enabling our bodies’ T-cell armies to attack the tumour microenvironment. In support of our immunotherapy efforts, Roche’s research and development team managed to separate the 200+ known cancer types into 3 primary immune profiles: inflamed tumours, immune excluded tumours and immune deserts. Understanding these profiles helps us develop different treatment strategies that allow us to target each individual’s immune biology.

The cancer immunity cycle is a framework that helps to explain how tumours interact with the human immune system. Listen as Roche Global Head of Cancer Immunotherapy Dan Chen and Vice President of Cancer Immunology Ira Mellman provide simple explanations of immunotherapy and the cancer immunity cycle.

To learn more about Roche’s commitment to cancer immunotherapy, visit http://www.roche.com/cancer-immunotherapy.

Subscribe to our YouTube channel now: https://www.youtube.com/user/roche?sub_confirmation=1

Get in touch with us:

https://www.roche.com/
https://www.facebook.com/RocheCareers
https://www.linkedin.com/company/roche
Tweets by Roche

Roche has been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally.

Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience.

For more information and insights visit: https://www.roche.com/